Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Biotech
Contineum-J&J drug fails to improve vision in phase 2 MS trial
The Johnson & Johnson-partnered asset failed to trigger any significant change in vision acuity for MS patients.
Gabrielle Masson
Nov 20, 2025 5:26pm
J&J pays $3B cash for Halda's cancer cell death tech
Nov 17, 2025 10:19am
BMS-J&J blood thinner fails phase 3, denting blockbuster hopes
Nov 14, 2025 8:10am
Fierce Pharma
J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T
Nov 12, 2025 11:36am
FDA reveals 2nd round of 'national priority' voucher winners
Nov 6, 2025 3:12pm
Nanobiotix finds new way to source cash from J&J-partnered drug
Oct 31, 2025 6:05am
